PipelineReview.com6h
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I 30, 2024 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...
PipelineReview.com11h
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
PLANEGG-MARTINSRIED, Germany I 30, 2024 I Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi jointly announce that ...
PipelineReview.com11h
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China I 30, 2024 I Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative ...
PipelineReview.com11h
Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company
PARIS, France I 30, 2024 I Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company leading the way in the ...